5-(5-methyl-1,3,4-oxadiazol-2-yl)-2-thiophenecarboxylic acid | 133380-72-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: 5-(5-methyl-1,3,4-oxadiazol-2-yl)-2-thiophenecarboxylic acid
• 英文别名: 5-(5-Methyl-1,3,4-oxadiazol-2-yl)thiophene-2-carboxylic acid
• CAS: 133380-72-0
• 化学式: C₈H₆N₂O₃S
• 分子量: 210.213
• InChiKey: RWZAVEAWGCYEIG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  105
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  methyl 5-(5-methyl-1,3,4-oxadiazol-2-yl)-2-thiophenecarboxylate 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 2.5h， 以75%的产率得到5-(5-methyl-1,3,4-oxadiazol-2-yl)-2-thiophenecarboxylic acid
  参考文献：
  名称：

  5-杂芳基-2-噻吩羧酸：恶唑和恶二唑

  摘要：

  报道了带有烷基和芳基取代的恶唑和恶二唑环的新型噻吩-2-羧酸的合成。关键前体5-甲酰基-2-噻吩羧酸的顺序官能化提供了中间体羧酸酯，其通过碱性裂解被转化为所需的酸。

  DOI：

  10.1002/jhet.5570280104

文献信息

• 3-substituted-2-oxindole derivatives
  申请人：Pfizer Inc.

  公开号：US05047554A1

  公开（公告）日：1991-09-10

  This invention relates to novel 3-substituted-2-oxindole derivatives which are inhibitors of prostaglandin H.sub.2 synthase, 5-lipoxygenase and interleukin-1 biosynthesis. The compounds of the invention are useful as inhibitors of prostaglandin H.sub.2 synthase and interleukin-1 biosynthesis, per se, and as analgesic, antiinflammatory and antiarthritic agents in the treatment of chronic inflammatory diseases. This invention also relates to pharmaceutical compositions comprising said 3-substituted-2-oxindole derivatives; to methods of inhibiting prostaglandin H.sub.2 synthase and biosynthesis of interleukin-1; and to treating chronic inflammatory diseases in a mammal with said compounds. Further, this invention relates to certain novel carboxylic acids useful as intermediates in the preparation of the 3-substituted-2-oxindole derivatives of this invention and to a process for the preparation of the 3-substituted-2-oxindole derivatives.

  这项发明涉及新型的3-取代-2-噁唑烷酮衍生物，这些衍生物是前列腺素H.sub.2合酶、5-脂氧合酶和白细胞介素-1生物合成的抑制剂。该发明的化合物在慢性炎症性疾病的治疗中可用作前列腺素H.sub.2合酶和白细胞介素-1生物合成的抑制剂，本身也可作为镇痛、抗炎和抗关节炎药物。本发明还涉及包含所述3-取代-2-噁唑烷酮衍生物的药物组合物；抑制前列腺素H.sub.2合酶和白细胞介素-1生物合成的方法；以及使用这些化合物治疗哺乳动物的慢性炎症性疾病。此外，本发明还涉及某些新型羧酸，可用作本发明的3-取代-2-噁唑烷酮衍生物的合成中间体，以及一种制备这些衍生物的方法。
• 3-substituted-2-oxindole derivatives as antiinflammatory agents
  申请人：PFIZER INC.

  公开号：EP0393936A1

  公开（公告）日：1990-10-24

  This invention relates to novel 3-substituted-2-oxindole derivatives which are inhibitors of prostaglandin H2 synthase, 5-lipoxygenase and interleukin-1 biosynthesis. The compounds of the invention are useful as inhibitors of prostaglandin H2 synthase and interleukin-1 biosynthesis, per se, and as analgesic, antiinflammatory and antiarthritic agents in the treatment of chronic inflammatory diseases. This invention also relates to pharmaceutical compositions comprising said 3-substituted-2-oxindole derivatives; to methods of inhibiting prostaglandin H2 synthase and biosynthesis of interleukin-1; and to treating chronic inflammatory diseases in a mammal with said compounds. Further, this invention relates to certain novel carboxylic acids useful as intermediates in the preparation of the 3-substituted-2-oxindole derivatives of this invention and to a process for the preparation of the 3-substituted-2-oxindole derivatives.

  本发明涉及新型 3-取代-2-氧化吲哚衍生物，它们是前列腺素 H2 合酶、5-脂氧合酶和白细胞介素-1 生物合成的抑制剂。本发明的化合物本身可用作前列腺素 H2 合酶和白细胞介素-1 生物合成的抑制剂，也可用作治疗慢性炎症性疾病的镇痛、抗炎和抗关节炎药物。本发明还涉及包含所述 3-取代-2-氧化吲哚衍生物的药物组合物；涉及抑制前列腺素 H2 合酶和白细胞介素-1 生物合成的方法；涉及用所述化合物治疗哺乳动物的慢性炎症疾病。此外，本发明还涉及某些可用作制备本发明 3-取代-2-吲哚衍生物中间体的新型羧酸，以及制备 3-取代-2-吲哚衍生物的工艺。
• Spirocyclic containing compounds and pharmaceutical uses thereof
  申请人：GB005, Inc.

  公开号：US10752615B2

  公开（公告）日：2020-08-25

  The present invention relates to a novel family of covalent kinases inhibitors, compounds of this class have been found to have inhibitory activity against members of the TEC kinase family, particularly ITK and/or TXK, BTK, TEC and/or combinations thereof. The present invention is directed to a compound of Formula I or pharmaceutically acceptable salt, solvate, solvates of salt, stereoisomer, tautomer, isotope, prodrug, complex or biologically active metabolite thereof, for use in therapy.

  本发明涉及一种新型的共价激酶抑制剂家族，已发现该类化合物对TEC激酶家族成员，特别是ITK和/或TXK、BTK、TEC和/或其组合具有抑制活性。本发明涉及一种用于治疗的式I化合物或其药学上可接受的盐、溶解物、盐的溶解物、立体异构体、同分异构体、同位素、原药、复合物或生物活性代谢物。
• GODDARD, CARL J., J. AFIEROCYCL. HETEROCYCL. , 28,(1991) N, C. 17-28
  作者：GODDARD, CARL J.

  DOI：——

  日期：——
• SPIROCYCLIC CONTAINING COMPOUNDS AND PHARMACEUTICAL USES THEREOF
  申请人：GB005, Inc.

  公开号：US20190263790A1

  公开（公告）日：2019-08-29

  The present invention relates to a novel family of covalent kinases inhibitors, compounds of this class have been found to have inhibitory activity against members of the TEC kinase family, particularly ITK and/or TXK, BTK, TEC and/or combinations thereof. The present invention is directed to a compound of Formula I or pharmaceutically acceptable salt, solvate, solvates of salt, stereoisomer, tautomer, isotope, prodrug, complex or biologically active metabolite thereof, for use in therapy.